Summary

Eligibility
for males ages 18 years and up (full criteria)
Location
at San Francisco, California
Dates
study started
completion around
Principal Investigator
by Robert Bok, MD, PhD
Headshot of Robert Bok
Robert Bok

Description

Summary

This is a Phase 2 clinical study of hyperpolarized (HP) 13C-pyruvate (13C), 15N-urea (13C,15N) metabolic MR imaging in prostate cancer patients who are undergoing or have received radiation therapy for prostate cancer.

Official Title

A Phase 2 Study of Magnetic Resonance (MR) Imaging With Hyperpolarized 13C-Pyruvate +/- 13C,15N-Urea in Patients With Prostate Cancer Undergoing Radiation Therapy

Details

Keywords

Prostate Cancer, Imaging Studies, Hyperpolarized 13C-Pyruvate, Prostatic Neoplasms, Hormones, hyperpolarized pyruvate +/-urea (13C/15N), Non-investigational Stereotactic body radiotherapy (SBRT), Radiotherapy (RT), Multi-parametric magnetic resonance imaging (mpMRI), Non-interventional hormone therapy, Prostate Biopsy

Eligibility

Location

  • UCSF accepting new patients
    San Francisco California 94143 United States

Lead Scientist at UCSF

  • Robert Bok, MD, PhD
    Robert Bok, MD, PhD, is a Professor in the Department of Radiology and Biomedical Imaging and the Hyperpolarized MRI Technology Resource Center at the University of California, San Francisco. Dr. Bok obtained his PhD in Biochemistry from the University of Illinois in 1984, and he earned his MD in Medicine from The Johns Hopkins University, Baltimore in 1989.

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Robert Bok, MD, PhD
ID
NCT06391034
Phase
Phase 2 Prostate Cancer Research Study
Study Type
Interventional
Participants
Expecting 161 study participants
Last Updated